Trials Offered by a Specific Doctor

TAUB INSTITUTE
Investigator
Lawrence Honig, MD, PhD
Email
lh456@columbia.edu

Lawrence Honig, MD, PhD, is a Professor of Clinical Neurology at Columbia University College of Physicians and Surgeons (New York, NY), in the Department of Neurology (Division of Aging and Dementia), Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and the Gertrude H. Sergievsky Center. He is Director of the Clinical Core of the Alzheimer's Disease Research Center at Columbia University.

Dr. Honig obtained his MD medical degree from the University of Miami (Miami, Florida), and his PhD from the University of California at Berkeley (Berkeley, California). He underwent postgraduate internship in Medicine and residency in Neurology training at Stanford University Medical Center (California). He served on the faculty of the Neurology departments at Stanford University Medical Center, and then at the University of Texas Southwestern Medical Center in Dallas, prior to his arrival at Columbia University in the year 2000. His research interests are in Alzheimer's Disease, Lewy Body Dementia, Frontotemporal Dementia, Creutzfeldt-Jakob disease, and other disorders of nervous system aging and degeneration. In addition to directing the Clinical Core of the Alzheimer's Disease Research Center at Columbia University, he conducts a number of clinical drug study trials, and also engages in clinical patient care at NewYork-Presbyterian Hospital and at the Lucy G. Moses Center for Memory and Behavioral Disorders, in the Neurological Institute.


Clinical Studies Managed By Dr. Honig:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study assessing the safety and effectiveness of study drug Crenezumab in patients with mild to moderate Alzheimer's DiseaseGenentech, Inc.AAAO8808
Details[CLOSED] A study for patients with early Alzheimer's Disease using study drug AZD3293AstraZenecaAAAP6613
Details[CLOSED] A study for patients with Progressive Supranuclear Palsy (PCP) using study drug C2N-8E12C2N DiagnosticsAAAP6502
Details[CLOSED] A study for patients with Progressive Supranuclear Palsy using study drug BMS-986168BMSAAAP6503
Details[CLOSED] A study for patients with Alzheimer's Disease using study drug azeliragon (TTP488)vTvAAAQ6252
Details[CLOSED] A study for patients with Alzheimer's disease using study drug crenezumabGenentech, Inc.AAAQ6304
Details[CLOSED] A study for patients with dementia using study drug RVT-101Axovant SciencesAAAQ7705
DetailsA study of safety and efficacy of IV BMS-986168 in patients with Progressive Supranuclear Palsy.BiogenAAAR2560
Details[CLOSED] Magnetic Resonance Spectroscopy (MRS) to assess progression of Alzheimer Disease (AD)Alzheimer's Disease Drug Discovery FoundationAAAK3001
DetailsMissionAD1: A 24-month Efficacy and Safety Study in Subjects with Early Alzheimer's DiseaseEISAIAAAR2556
DetailsStudy of New Drug in Patients with Cognitive Impairment or Mild Alzheimer's DiseaseF. Hoffmann- La Roche Ltd.AAAR6021